American Chemical Society
Nonprofit profile at a glance
- EIN
- 396065798
- IRS 990 coverage
- 2015–2025
- Forms available
- Form 990 2025
- Location
- Arlington, MA, USA
- Phone
- 7812963867
- Rating
- 77
- Verdict
- SUPPORTED
- Rating confidence
- Moderate
Reported finances
- Revenue
- $1,645,539
- Expenses
- $1,297,461
- Assets
- $1,025,411
- Liabilities
- $10,028
Source: IRS Form 990. Selected filing: tax year 2025. Amounts in USD.
Leadership & pay
19 people listed
People named in this filing
- Michelle O'Malley (Awards Chair)
- John Kim (Past Chair)
- Aaron Noyes (Chair)
Selected names, not a complete roster or a statement of current roles. Open leadership details for the complete filed list.
Source: IRS Form 990. Selected filing: tax year 2025. Names and roles reflect this filing, not necessarily current officeholders.
Overview
Mission
To promote the exchange of information among academic and industrial researchers regarding technology utilizing life-based systems to produce useful products and services.
What it reported doing in 2025
Bi-annual Scientific Symposia in Biotechnology hosted by the Recovery of Biological Products Conference Series and ACS Division of Biochemical Technology. The biennial Conferences are an international crossroads where academia meets industry in the pursuit of cutting edge and trans-disciplinary science and technology. The meetings are characterized by active participation, dynamic exchange of ideas and views on nascent and emerging technologies and discussion of the future impact of peripheral sciences on the industrial application of recovery technologies. Oral and poster sessions, workshops and panel discussions are organized to focus on a systematic and integrated approach to process design and to strengthen the bridge between academic discovery and industrial implementation, resolution of industrial issues and decision-making in product development. Leading regulatory presence assures a dialog essential to product safety and the timely introduction of novel, ground breaking treatment of unmet medical needs. To maintain the scientific standards and quality of the Conference, participation is limited and by invitation. Leaders in the field of biological product recovery and related sciences are able to exchange innovative ideas in an atmosphere free from commercial, corporate or publishing pressures, in locations which are conducive to networking, building fruitful professional relationships, making new friends and renewing old friendships.
Operating model
- Revenue model
- Mixed. Its operating money came from several sources; no one source provided a clear majority.
- Distribution model
- Direct operator. The filing allocates 98% of reported program-service expenses outside its grant, affiliate-payment, and member-benefit lines. This expense classification does not rule out separately announced grant awards.
The verdict
SUPPORTED - The filed numbers largely add up and a large share of available resources goes toward mission work. Some filing-based governance responses are negative or unanswered and total assets are small relative to annual expenses; liquid coverage is unknown.
Rating breakdown
- Financial Efficiency: 66
- Transparency & Controls: 94
- Accountability: 70
- Sustainability: 62
- Growth: 100
Detailed rating inputs
Financial Efficiency
- Mission deployment rate: 67.7%; rating input score 68
- Program expense ratio: 85.7%; rating input score 86
- Fundraising efficiency: Limited
Transparency & Controls
- Consistency checks: 100%; rating input score 100; 63rd percentile among comparable filings
- Pay-setting controls: Limited
- Foreign activity oversight: Limited
- Grant itemization coverage: 100%; rating input score 100; 78th percentile among comparable filings
- Major donor itemization: Yes; rating input score 100
- Related-party transparency: Limited
Accountability
- Independent voting board: 100%; rating input score 100; 64th percentile among comparable filings
- Governance controls: 2 of 7 controls in place; rating input score 29
- Conflict-of-interest policy: Fail
- Whistleblower policy: Fail
- Document-retention policy: Fail
- CEO compensation review process: NotApplicable
- Other executive compensation review process: NotApplicable
- Form 990 shared with the board: Pass
- Board meeting minutes documented: Pass
- Audit committee oversight: Missing
- Independent financial-statement audit: Fail
Sustainability
- Operating margin: 21.2%; rating input score 74; 74th percentile among comparable filings
- Total-asset coverage ratio: 0.79; rating input score 36; 36th percentile among comparable filings
- Liabilities to assets ratio: 0.01; rating input score 60; 60th percentile among comparable filings
- Officer compensation ratio: 0%; rating input score 78; 78th percentile among comparable filings
Growth
- Program expense growth: 1.9% per year; rating input score 100; 22nd percentile among comparable filings
- Revenue growth: 3% per year; rating input score 100; 25th percentile among comparable filings
- Asset growth: 0.2% per year; rating input score 100; 16th percentile among comparable filings
Details
- Where the money goes: 67.7% of revenue deployed · 85.7% of spending went to programs
- Governance: 19 of 19 board members independent · 2 of 7 filing controls reported
- Programs: 1 filed program accomplishment · $1.1M in reported program spending
- Leadership: top reported pay $0 · 19 people listed
- Consistency: 19 of 19 current checks pass
- Schedules: 4 filed schedules · includes major donors and grants
- Filing history: 10 filing years from 2015 to 2025
- Contacts: How to reach this organization
- Grant readiness: Federal tax and exclusion status, award history, and grant-maker relationships.
- People: Everyone the filings name, and which of them the filings identify by more than a name.
Key Signals
Signals prioritize questions for review. They are not findings of misconduct.
- High — Accountability: Governance controls: 4 of 6 not reported.
- Moderate — Sustainability: Total-asset coverage ratio scored 36/100.